About Us
Founded in 1944, the American Committee for the Weizmann Institute of Science develops philanthropic support for the Weizmann Institute in Israel, and advances its mission of science for the benefit of humanity.
This virtual conversation, hosted by the American Committee, features Weizmann’s Dr. Ravid Straussman, the NIH’s Dr. Daniel Douek (Chief of the Human Immunology Section of the Vaccine Research Center), and is moderated by Dr. Alan Leishner, former CEO of the American Association for the Advancement of Science, which publishes the prestigious journal Science.
December 17, 2020
A new cancer therapy gives us all hope. This latest breakthrough combines photo-dynamic therapy using laser light with a novel drug to treat early-stage prostate cancer. The combination makes it possible to safely treat cancerous tissue using a minimally invasive procedure, with none of the side effects of surgery or radiation.
Dr. Jonathan Coleman, MD, Memorial Sloan Kettering Cancer Research Center, and Prof. Avigdor Scherz, Weizmann Institute of Science, discuss ongoing clinical trials at MSKCC testing vascular targeted photodynamic therapy for prostate cancer. Developed at the Weizmann Institute, this revolutionary treatment uses light emitted by optical fibers that are inserted into the prostate (and possibly other areas), activating a drug that destroys cancer cells—with little side effects.
Summer is here! But more fun in the sun also increases our risk for skin cancer, including its deadliest form, melanoma. In the seventh episode of Weizmann in Focus, CEO Dave Doneson highlights a melanoma research breakthrough by Prof. Yardena Samuels, which could lead to “the ultimate personalized cancer therapy.”
The Weizmann Institute brings together scientists from a variety of disciplines to tackle cancer head-on. In the fourth episode of Weizmann in Focus, CEO Dave Doneson highlights a recent headline-making breakthrough from the labs of Profs. Ido Amit and Amos Tanay. Working with hospitals across Israel, the scientists identified a very small number of malignant cells in what is considered a pre-malignant stage of multiple myeloma—the second-most common type of blood cancer. Their discovery holds the promise of earlier, more precise treatment.
May 25, 2017
December 22, 2016
November 01, 2016
Reporter Natasha Kirtchuk describes the new prostate cancer treatment developed by the Weizmann Institute's Profs. Avigdor Scherz and Yoram Salomon, along with an extended team of scientists, researchers, oncologists, urologists, clinicians, technicians, and more. The therapy involves no radiation or chemotherapy, takes just 90 minutes to complete...
June 17, 2016
©2021 American Committee for the Weizmann Institute of Science